Choose a language and wait for the translated text.
β On a press call, executives said some departments face cutbacks or restructuring, while others will re-skill and hire for emerging needs. Soriot said shifting βfocus from patent-expiring drugs such as Farxiga and Brilinta to oncology and rare diseases could render some R&D roles redundant.
AstraZeneca kicks off $1.5 billion savings drive to invest in drug pipeline | PharmaVoice
